<code id='C0448059FA'></code><style id='C0448059FA'></style>
    • <acronym id='C0448059FA'></acronym>
      <center id='C0448059FA'><center id='C0448059FA'><tfoot id='C0448059FA'></tfoot></center><abbr id='C0448059FA'><dir id='C0448059FA'><tfoot id='C0448059FA'></tfoot><noframes id='C0448059FA'>

    • <optgroup id='C0448059FA'><strike id='C0448059FA'><sup id='C0448059FA'></sup></strike><code id='C0448059FA'></code></optgroup>
        1. <b id='C0448059FA'><label id='C0448059FA'><select id='C0448059FA'><dt id='C0448059FA'><span id='C0448059FA'></span></dt></select></label></b><u id='C0448059FA'></u>
          <i id='C0448059FA'><strike id='C0448059FA'><tt id='C0448059FA'><pre id='C0448059FA'></pre></tt></strike></i>

          Home / fashion / comprehensive

          comprehensive


          comprehensive

          author:entertainment    Page View:2

          Editor’s note: A recording of the event is embedded below.

          After a few go-go years, the early-stage biotech market has cooled considerably. Two VCs will weigh in on what distinguishes great science from bad investments.

          advertisement

          Featured Speakers

          • Irena Melnikova, Ph.D., partner, Pfizer Ventures
          • Rakhshita Dhar, senior director, venture investments, Leaps by Bayer
          • Frank S. David, M.D., Ph.D., managing director, Pharmagellan (moderator)

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In